ClinicalTrials.Veeva

Menu

Patient-derived Organoids of Lung Cancer to Test Drug Response

University Hospitals (UH) logo

University Hospitals (UH)

Status

Enrolling

Conditions

Organoid
Lung Cancer

Treatments

Procedure: Lung tumor resection

Study type

Observational

Funder types

Other

Identifiers

NCT03979170
2018-02395

Details and patient eligibility

About

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Full description

The aim of the project is to use a combination of patient-derived organoid models:

  • To amplify tumour tissue to obtain enough material for genomic and histological analysis
  • to characterize the lung cancer sub-type
  • To predict treatment (non)response.

The following points will be addressed:

  1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour.
  2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically proven lung cancer
  • Age ≥ 18
  • Written informed and signed consent
  • Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion criteria

  • Less than 18 years of age
  • Not able to give informed consent (language, intellectual capacities, etc.)
  • Not accessible to biopsy and/or surgery sample
  • Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

Trial contacts and locations

1

Loading...

Central trial contact

Veronique SERRE-BEINIER, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems